JP2019501112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501112A5 JP2019501112A5 JP2018521887A JP2018521887A JP2019501112A5 JP 2019501112 A5 JP2019501112 A5 JP 2019501112A5 JP 2018521887 A JP2018521887 A JP 2018521887A JP 2018521887 A JP2018521887 A JP 2018521887A JP 2019501112 A5 JP2019501112 A5 JP 2019501112A5
- Authority
- JP
- Japan
- Prior art keywords
- epha4
- condition
- disease
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- 102000021727 EphA4 Receptor Human genes 0.000 claims description 8
- 108010055179 EphA4 Receptor Proteins 0.000 claims description 8
- 230000004988 N-glycosylation Effects 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 230000010410 reperfusion Effects 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000026072 Motor neurone disease Diseases 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000005264 motor neuron disease Diseases 0.000 claims description 6
- 230000000626 neurodegenerative effect Effects 0.000 claims description 6
- 150000001508 asparagines Chemical class 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 23
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 206010018341 Gliosis Diseases 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 206010061431 Glial scar Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015904387A AU2015904387A0 (en) | 2015-10-27 | A method of treatment and agents useful for same | |
| AU2015904387 | 2015-10-27 | ||
| PCT/AU2016/051010 WO2017070738A1 (en) | 2015-10-27 | 2016-10-27 | A method of treatment and agents useful for same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501112A JP2019501112A (ja) | 2019-01-17 |
| JP2019501112A5 true JP2019501112A5 (enExample) | 2019-12-05 |
| JP6877419B2 JP6877419B2 (ja) | 2021-05-26 |
Family
ID=58629613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521887A Active JP6877419B2 (ja) | 2015-10-27 | 2016-10-27 | 治療の方法およびそのために有用な剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10617738B2 (enExample) |
| EP (1) | EP3368551B1 (enExample) |
| JP (1) | JP6877419B2 (enExample) |
| CN (1) | CN108884135B (enExample) |
| AU (1) | AU2016345063B2 (enExample) |
| ES (1) | ES2959601T3 (enExample) |
| WO (1) | WO2017070738A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110702916B (zh) * | 2019-04-15 | 2022-06-21 | 四川大学华西医院 | 一种整合蛋白质组和糖蛋白组的定量分析方法 |
| EP4308149A4 (en) * | 2021-03-18 | 2025-02-26 | Valery Krasnoperov | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
| AU2022388189A1 (en) * | 2021-11-11 | 2024-05-02 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| WO2023154948A1 (en) * | 2022-02-14 | 2023-08-17 | Vasgene Therapeutics Inc. | Ephrin type-b receptor 4 (ephb4) agents and production thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| EP0425731B1 (de) | 1989-11-03 | 1994-01-19 | Siemens Aktiengesellschaft | Controller-Bussystem für einen programmierbaren, flexiblen Digitalsignal-Multiplexer |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| DE69423522T2 (de) | 1993-04-27 | 2000-09-21 | Cytotherapeutics, Inc. | Membran aus einem acrylnitrilpolymer |
| NZ269041A (en) | 1993-06-23 | 1998-02-26 | Univ Brown Res Found | Implantable encapsulation device having a cell-tight dry seal at an opening thereof |
| SG48813A1 (en) | 1993-08-12 | 1998-05-18 | Cytotherapeutics Inc | Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5853717A (en) | 1994-07-20 | 1998-12-29 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| CA2202747A1 (en) | 1995-06-01 | 1996-12-05 | Dennis Keen Warren | Communication system to provide called party location and pre-call warning |
| IN181898B (enExample) | 1995-06-07 | 1998-10-24 | Cytotherapeutics Inc | |
| WO1997012635A1 (en) | 1995-10-02 | 1997-04-10 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| JP2007525203A (ja) * | 2004-02-27 | 2007-09-06 | オンコセラピー・サイエンス株式会社 | ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４ |
| US20080003210A1 (en) | 2006-03-13 | 2008-01-03 | Medimmune, Inc. | Non-human primate receptor tyrosine kinases |
| WO2008150010A1 (ja) * | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
| EP2223999B1 (en) * | 2007-11-30 | 2017-10-18 | Eisai R&D Management Co., Ltd. | Epha4 polypeptide having novel activity and use thereof |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| EP2653552B1 (en) * | 2010-12-17 | 2016-10-19 | Eisai R&D Management Co., Ltd. | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR |
| MY199344A (en) | 2013-02-18 | 2023-10-24 | Vegenics Pty Ltd | Ligand binding molecules and uses thereof |
-
2016
- 2016-10-27 AU AU2016345063A patent/AU2016345063B2/en active Active
- 2016-10-27 CN CN201680074679.6A patent/CN108884135B/zh active Active
- 2016-10-27 US US15/771,788 patent/US10617738B2/en active Active
- 2016-10-27 EP EP16858502.4A patent/EP3368551B1/en active Active
- 2016-10-27 WO PCT/AU2016/051010 patent/WO2017070738A1/en not_active Ceased
- 2016-10-27 ES ES16858502T patent/ES2959601T3/es active Active
- 2016-10-27 JP JP2018521887A patent/JP6877419B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Targeting IL-10 family cytokines for the treatment of human diseases | |
| Fang et al. | HMGB1 in development and diseases of the central nervous system | |
| Ydens et al. | Acute injury in the peripheral nervous system triggers an alternative macrophage response | |
| Brines | The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors | |
| JP6938565B2 (ja) | Ｕｔｉ融合タンパク質 | |
| US11365229B2 (en) | Methods of treating neurological diseases | |
| SI2860251T1 (en) | Aptameric therapeutics useful in the treatment of complement-related disorders | |
| CA2935599A1 (en) | Il-15 heterodimeric protein and uses thereof | |
| US20150141499A1 (en) | Engineered nucleic acids and methods of use thereof | |
| JP2011530599A5 (enExample) | ||
| CN118873680A (zh) | 用于治疗目的的抗体-脲酶缀合物 | |
| JP7830450B2 (ja) | 修飾されたｉｌ－２分子及びその用途 | |
| US20050181981A1 (en) | Method of treatment | |
| KR20080027291A (ko) | 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법 | |
| JP2021046437A (ja) | サイトカインストーム抑制剤 | |
| KR20000053277A (ko) | 가용성 폴리펩티드 | |
| CN117946213A (zh) | 治疗癌症的肽 | |
| US8802625B2 (en) | Methods for promoting organ development | |
| Kalinin et al. | Astrocyte lipocalin-2 modestly effects disease severity in a mouse model of multiple sclerosis while reducing mature oligodendrocyte protein and mRNA expression | |
| US8716222B2 (en) | Methods and compositions for promoting organ development | |
| KR101025352B1 (ko) | 생리활성 복합체 | |
| JP5266460B2 (ja) | 腎不全を治療するための方法 | |
| CN117924430B (zh) | 促进血小板生成的tpor结合肽 | |
| KR20120099161A (ko) | 돌연변이된 뉴블라스틴의 중합체 컨주게이트 | |
| TWI887237B (zh) | 用於製備粒細胞群落刺激因子的方法 |